ArticlePharmacoepidemiology and drug safety2026
Pediatric Use of Off-Label Medicines and Nonevidence-Based Supplements for COVID-19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil).
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric Use of Off-Label Medicines and Nonevidence-Based Supplements for COVID-19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil).Pharmacoepidemiology and drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePediatric off-label medicine use increased during the COVID-19 pandemic, exposing children to nonevidence-based treatments. We described the use of nonevidence-based COVID-19 medicines and supplements among children from the 2015 Pelotas Birth Cohort, according to sociodemographic and health-related characteristics.
methodsData from the 6-7-year follow-up were analyzed. Mothers/caregivers reported children's use of nonevidence-based medicines (azithromycin, chloroquine/hydroxychloroquine, ivermectin, nitazoxanide) and supplements (vitamin C, vitamin D, and zinc) along with sociodemographic and health-related characteristics. Two scores were analyzed: (1) child's COVID-19 burden score (considering negative experiences such as death or separation from a close person due to COVID-19, and risk factors such as living with older adults or having asthma, bronchitis, or obesity) and (2) preventive behavior score (limited outdoor exposure during COVID-19 and vaccine uptake against COVID-19). Hierarchical logistic regression analyses were used to identify factors associated with nonevidence-based medicine and supplement use.
resultsAmong 3098 children interviewed after COVID-19 vaccines became available in the municipality, 13.9% (95% CI 12.7-15.2) used nonevidence-based medicines and supplements for COVID-19. Overall, the use of nonevidence-based medicines and supplements increased with higher COVID-19 burden scores and decreased with higher preventive behavior scores. Unvaccinated children had 2.57-fold higher odds of using off-label medicines than vaccinated children.
conclusionsThese findings highlight behavioral responses during a health emergency and suggest that public health policies should strengthen evidence-based risk communication and discourage inappropriate medicine use during future health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.